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ABSTRACT: Cadherins are transmembrane cell adhesion proteins whose aberrant expression often correlates with cancer 
development and proliferation. We report the crystal structure of an E-cadherin extracellular fragment in complex with a 
peptidomimetic compound that was previously shown to partially inhibit cadherin homophilic adhesion. The structure 
reveals an unexpected binding mode and allows the identification of a druggable cadherin interface, thus paving the way 
to a future structure-guided design of cell adhesion inhibitors against cadherin-expressing solid tumors. 
INTRODUCTION 
Cadherins are transmembrane calcium-dependent cell 
adhesion molecules that are mostly localized at the inter-
cellular junctions and are known to play a crucial role in 
tissue morphogenesis and architectural integrity.1,2 Many 
functional studies have shown that aberrant expression of 
epithelial E-cadherin (CDH1) and neuronal N-cadherin 
(CDH2) often correlates with tumor progression.3,4 In fact, 
the switch in expression from E-to N-cadherin is a key 
event in the cellular epithelial-to-mesenchymal transition 
(EMT) that takes place as cancer progresses. Despite its 
tumor repressor role in the majority of carcinomas, in epi-
thelial ovarian cancer (EOC) cells E-cadherin shows a 
high level of expression during tumor progression and fa-
cilitates EOC cell proliferation.5 Interestingly, most cad-
herin family members are now being considered im-
portant pharmaceutical targets. For instance, a role for P-
cadherin (CDH3) in different types of cancer, such as in 
malignant melanoma, breast, gastric, lung, colorectal and 
pancreatic cancer has also been clearly identified.6,7 
Therefore, efforts to develop therapeutic agents against P-
cadherin have recently intensified.8 Likewise, increased 
expression of cadherin-11 (CDH11) on poorly differentiated 
highly invasive breast cancer cell lines is also associated 
with EMT and tumor progression.9,10 Furthermore, cad-
herin-11 is a validated therapeutic target in rheumatoid 
arthritis (RA).11 Hence, efforts to develop effective thera-
peutic agents against cadherin-11 are also under way.12 
Cadherins mediate cell-cell adhesion by means of a 
concerted mechanism whereby proteins protruding from 
opposing cells interact with each other at the cellular ad-
herens junctions. All classical cadherin family members 
share a high degree of homology and structural similarity. 
Classical cadherins comprise an elongated extracellular 
portion formed by five immunoglobulin-like extracellular 
cadherin domains (ECs) arranged in tandem, and an in-
tracellular portion whose dynamic association with cyto-
plasmic molecules called catenins provides a physical link 
between the membrane-bound cadherins and the actin 
cytoskeleton. Structural and mutational studies on several 
type-I classical cadherin family members such as E-, N-, 
P- and C-cadherin have clearly shown that dimerization 
of two cadherin molecules protruding from the surface of 
two neighboring cells at the adherens junction occurs 
through a highly dynamic strand-exchange mechanism 
involving the opening of a 6-residue long N-terminal por-
tion of the protein, usually referred to as the adhesion 
arm, and the mutual insertion of the side chain of the 
conserved Trp2 residue into the highly conserved accep-
tor pocket in the EC1 of the partner molecule (Fig. 1, A 
and C).13-19 Likewise, in type-II classical cadherins, such as 
cadherin-11, cadherin-8 and MN-cadherin, a similar 
 mechanism involves the simultaneous mutual insertion of 
the side chain of the conserved Trp2 and Trp4 residues 
into the binding pockets in the partner molecule’s EC1, 
providing a tighter link and a larger interface between the 
two interacting monomers relative to type-I cadherins.20,21 
Figure 1 Schematic of the dynamic dimerization mechanism that 
leads from monomeric cadherin (A) to strand swap dimer for-
mation (C) and back. The mechanism is characterized by the 
opening of the adhesion arm of two interacting cadherins and the 
mutual insertion of the Trp2 side chain in the binding pocket of 
the partner molecule. This process occurs via the formation of a 
weakly adhesive intermediate configuration which is usually re-
ferred to X-dimer (B) and has been shown to facilitate arm open-
ing by lowering the energy barrier associated with strand swap 
dimer formation. 
Interestingly, the highly dynamic cadherin dimerization 
pathway that leads from monomeric cadherin to strand-
dimer formation and back involves a number of crucial 
intermediate steps that are critical not only for cell adhe-
sion but also for conferring specificity to the cellular 
recognition process during tissue morphogenesis. Along 
the complex trajectory that leads from monomers to 
strand-swap dimers and back, cadherins have been shown 
to go through an intermediate dimeric state characterized 
by stabilizing contacts between two cadherin molecules at 
the level of their Ca2+-binding site between the EC1 and 
EC2 domains (Fig. 1, B). This arrangement, usually re-
ferred to as the X-dimer14,15,22-24, provides a weak adhesive 
force between cadherin molecules25 and facilitates subse-
quent strand-swap dimer formation by lowering the ener-
gy barrier associated with the strand swapping process, 
suggesting that X-dimer formation is one of the major 
structural “checkpoints” along the cadherin dimerization 
pathway that leads from monomeric cadherin to strand 
dimer formation.26 A Kd value in the sub-millimolar range 
has been estimated for the homophilic adhesion of classi-
cal type I cadherins.23,27 
Owing to this intrinsic dynamic behavior, the rational 
design of small ligands targeting cadherin homophilic in-
teractions has proved difficult and, to date, no crystal 
structure exists of a complex between a cadherin mole-
cule and an inhibitor. Early structural studies suggested 
an important contribution of the His79-Ala80-Val81 
(HAV) and the Ile53-Asn54-Pro55 (INP) sequences to the 
cadherin homophilic binding mechanism.13 As a result, 
libraries of cyclic peptides based on HAV or INP sequenc-
es and of non-peptide HAV mimics were developed and 
tested for their ability to inhibit the cadherin dimeriza-
tion process.28-30 Based on these studies, the antagonist 
peptide N-Ac-CHAVC-NH2 (ADH-1 or Exherin™) is now 
in phase I clinical trials in patients with N-cadherin-
expressing solid tumors.31-33 However, its binding interface 
and mechanism of inhibition are still totally unknown. 
Protein-protein interfaces, especially homo-oligomers, 
are usually flat and featureless. Therefore, they are gener-
ally either completely undruggable or difficult to target 
with efficient antagonists.34,35 This is especially true for 
highly dynamic systems that undergo major conforma-
tional changes as part of their substrate recognition 
mechanism. The cadherin homo-dimerization and activa-
tion mechanism falls within this realm and it is not sur-
prising that, to date, almost no modulators or inhibitors 
of cadherin-mediated cell-cell adhesion have been devel-
oped. Moreover, no actual structural evidence regarding 
the mechanism through which successful modulation of 
cadherin homo-association may actually occur has yet 
been provided, thus making the development of effective 
antagonists particularly difficult. 
 
RESULTS AND DISCUSSION 
In one of the first attempts to target the cadherin strand 
dimer interface identified earlier by X-ray diffraction 
analysis, we have previously designed and synthesized a 
library of small peptidomimetic molecules featuring a 
conformationally constrained tetra-peptide scaffold from 
the native N-terminal DWVI sequence where a  
 
Figure 2 Structure of ADH-1 and FR159. Given their structural 
differences, it is unlikely that they share identical binding sites. 
 
phenyl ring was introduced to mimic the indole moiety of 
the crucial Trp2 residue.36 By a combination of biochemi-
cal and functional assays, we have also shown that, even 
at µM concentrations, some of these peptidomimetic 
compounds have a significantly higher ability to inhibit 
N- and, to a slightly lower extent, E-cadherin homophilic 
adhesion compared to ADH-1.36 For instance, FR159 (Fig. 
2) is more effective than ADH-1 in inhibiting both N- and 
E-cadherin homophilic binding. In ELISA tests using N-
cadherin-expressing epithelial ovarian cancer (EOC) cells 
SKOV3 and N-cadherin-Fc chimeric protein, FR159 inhib-
ited N-cadherin homophilic binding by 84% and by 
 
 Figure 3 Crystal structure of the human E-cadherin-(Val3)-
EC1EC2 fragment (residues 3-213) in its un-ligated form (PDB 
id: 4ZT1) (A) and in complex with FR159 (PDB id: 4ZTE) (B). 
65% at 2mM and at 1mM concentration, respectively, 
while ADH-1 showed 50% inhibition at 2mM concentra-
tion and virtually no inhibition at 1mM. Cell-free Surface 
Plasmon Resonance (SPR) experiments using the N-
cadherin-Fc recombinant protein showed that at 10µM 
concentration FR159 provides 55% inhibition of N-
cadherin homophilic binding, compared to 28% for ADH-
1. In ELISA tests conducted using the E-cadherin-
expressing EOC cell line OAW42 FR159 provided about 
50% inhibition at 2mM concentration, while ADH-1 
showed only 30% inhibition. Here, we show the crystal 
structure of the complex between the E-cadherin-EC1EC2 
fragment and FR159, one of the best inhibitory peptides 
that have been reported to date. The structure allows the 
identification of a novel druggable interface and provides, 
for the first time, a structural framework to guide the de-
sign of modulators of cadherin-mediated cell adhesion. 
Previous attempts to co-crystallize the wt-human E-
cadherin-EC1EC2 fragment (residues 1-213) with several 
small molecule ligands did not yield results, mostly owing 
to the highly dynamic behavior of the protein. We then 
removed the first two amino acids (Asp-Trp) at the N-
terminus of the EC1EC2 construct and produced the E-
cadherin-(Val3)-EC1EC2 fragment (residues 3-213), where 
the Trp2-binding pocket is intrinsically un-occupied and, 
in principle, more easily accessible to the ligand. Crystal-
lization of this shorter protein fragment with the same 
panel of peptidomimetic compounds yielded co-crystals 
only with FR159, likely owing to the intrinsic confor-
mation of the ligand. 
Fig.3 shows a side by side comparison of the E-
cadherin-(Val3)-EC1EC2 structure in the absence (A) and 
in the presence (B) of FR159. As expected, due to the re-
moval of the key Trp2 residue that is used by the protein 
in the final stage of its complex dimerization mechanism, 
the protein is unable to promote strand swap dimer for-
mation and it is found in the X-dimer configuration, an 
arrangement that has been previously shown to represent 
a crucial intermediate along the full cadherin dimeriza-
tion trajectory. In essence, by removing the Asp1-Trp2 N-
terminal fragment, we reduced the degree of conforma-
tional freedom of the cadherin association complex by 
preventing the X-dimer to progress towards strand swap 
dimer formation. A comparison of the two structures 
shows that the protein dimers superimpose with an 
r.m.s.d. of 0.4 Å for main chain atoms. 
 
Figure 4 Side by side comparison of the electron density map in 
the binding region between the un-ligated (A) and the ligated (B) 
structure (PDB id: 4ZT1 and 4ZTE, respectively). 
The preliminary computational studies that we carried 
out using both E- and N-cadherin suggested that the lig-
and may bind the protein by inserting the scaffold benzyl 
ring into the hydrophobic pocket of Trp2 and receive fur-
ther stabilization by a number of additional contacts with 
the protein (see the Supplementary Information for the 
best computational pose of FR159 into the E- and the N-
cadherin binding site).36 However, in the crystal the lig-
and does not bind in the expected Trp2 pocket and the X-
ray structure described here combined with previous cell 
adhesion inhibition data reveals a new target site for the 
design of cadherin inhibitors. In fact, the ligand binds 
across the two interacting cadherin molecules at the level 
of the di-proline motif of their adhesion arm. In the un-
ligated structure, several water molecules occupy the 
space that is taken by the peptidomimetic molecule in the 
ligated structure (Fig. 4). The phenyl ring of the pep-
tidomimetic ligand fits into an hydrophobic cavity formed 
by the side chains of residues Ile4, Pro5, Ile7 and Val22 
from both cadherin molecules. The Val3 residues from the 
two interacting molecules are not visible in the map but it 
is conceivable that they may transiently cap the hydro-
phobic cavity, thus providing further stabilization energy 
to the complex. The hydrophobic cavity is symmetrical as 
it is formed by exactly the same group of residues from 
the two interacting proteins. The electron density map of 
the ligand in the crystal is shown in Fig. 5, A while a 
schematic representation of the interactions between the 
phenyl ring of the ligand and the surrounding molecules 
is shown in Fig. 5, B. Interestingly, all the residues in-
volved in ligand stabilization are conserved across most 
type-I classical cadherins, suggesting a common general 
inhibitory mechanism associated with this peptidomimet-
ic compound for this cadherin subset.  
 Further hydrophobic contacts are formed by the tert-
butyl moiety that was introduced as a protective group at 
the C-terminus of the ligand and residues such as Thr97 
and Pro10 of the protein. However, this moiety of the lig-
and is rather disordered and therefore other contacts may 
be dynamically formed with neighboring residues. The 
isoleucine side chain of the peptide forms hydrophobic 
contacts with the side chain of Leu21 and Ile7 in the pro-
tein, providing further stabilization energy to the com-
plex. At the other moiety of the ligand, the Asp1 side 
chain of the peptidomimetic forms water-mediated con-
tacts with the carboxy group of Glu13 of the protein. Fi-
nally, in the central part of the peptidomimetic ligand, 
the carbonyl group of the heterocycle forms an hydrogen 
bonding interaction with the amide of Ser8 of the protein 
(2.81 Å). 
Each cadherin X-dimer has one inhibitor molecule 
bound between them. However, in the crystal the pep-
tidomimetic ligand is found in two alternative confor-
mations (each refined with 50% occupancy in the crystal 
structure), one rotated relative to the other around the 
approximate C2 axis of the complex (Fig. 5, A). Interest-
ingly, in the two alternative conformations the two ter-
minal moieties of the ligand are found in the same envi-
ronment and are stabilized by the same set of contacts 
with the protein. This is due to the C2 symmetry of the X-
dimer configuration and to the constrained “cis” confor-
mation of the ligand. 
 
CONCLUSION 
Here, we provide the first crystal structure of a cadherin 
fragment in complex with a small molecule inhibitor. This 
ligand has been previously shown to modulate and par-
tially inhibit cadherin-mediated cell adhesion better than 
ADH-1, a small cyclic peptide that is currently in phase I 
clinical trials in cancer patients. Whereas we predict that 
at some stage in the course of the dimerization process 
the cadherin binding pocket is also transiently targeted by 
the ligand through its phenyl ring moiety as part of a 
competitive mechanism with the Trp2 residue of the in-
tact adhesion arm of the protein itself,36 the crystal struc-
tures shown here provides clear evidence of an inhibitory 
mechanism whereby the ligand binds across the weakly 
adhesive X-dimer conformation at the level of the adhe-
sion arms of the two interacting cadherins. This suggests 
that in intact proteins, which unlike our N-terminally 
truncated fragment can form strand swap dimers, the 
binding of FR159 across the intermediate X-dimer pro-
vides a physical barrier against the progression of the sys-
tem towards strand dimer formation and blocks the sys-
tem at the weakly adhesive X-dimer conformation, as 
suggested by the binding inhibition data previously re-
ported. In line with these data, we have previously 
shown36 that FR159 can partially inhibit adhesion of E-
cadherin-expressing EOC cells, where E-cadherin plays a 
pro-proliferative role by mediating PI3K/AKT signaling 
activation.5 Interestingly, in the same E-cadherin-
expressing EOC cells, FR159 affects the activation of the 
PI3K/AKT signaling pathway (see Supporting Infor-
mation), indicating that indeed FR159 may help prevent 
or modulate the growth of EOC cells. 
Clearly, the novel structural details shown here allowed 
for the identification of a druggable pocket formed by two 
cadherin proteins in the weakly adhesive X-dimer con-
formation and provide unprecedented opportunities for a 
structure-based approach to the design and development 
of inhibitor compounds with enhanced efficacy against 
cadherin-expressing solid tumors. This could be especially 
relevant for relapsed EOC patients, in which tumor 
growth in the peritoneum may be inhibited by targeting 
up-regulated E-cadherin. Moreover, effective and selec-
tive cell-cell junctions modulator peptides may represent 
potential pharmaceutical excipients to improve drug de-
livery across biological barriers.37,38  
   
EXPERIMENTAL SECTION 
Figure 5 Electron density map of the ligand in the crystal of the complex between human E-cadherin-(Val3)-EC1EC2 and FR159 (PDB 
id: 4ZTE). The 2Fo-Fc map is shown at the 0.7 σ-level. A double conformation was found for the ligand, the two orientations forming 
exactly the same set of contacts with each of the two interacting protein fragments owing to the C2 internal symmetry of the complex 
(A). The stabilizing contacts between the ligand and the protein. For simplicity, only one of the two alternative orientations of the ligand 
are shown in the picture. Regardless of the orientation, the contacts formed by the ligand with the two interacting proteins are the same. 
Most contacts are hydrophobic in nature and are within the typical range distance for hydrophobic interactions (4.2-4.5 Å) (B). 
 Cloning, expression and purification of human E-
cadherin-EC1EC2 
A DNA fragment encoding for the EC1EC2 portion of 
human E-cadherin and lacking the first two N-terminal 
residues (Asp1-Trp2) was cloned into a pET-3a expression 
vector (Novagen) using the NdeI and BlpI restriction 
sites. This fragment, corresponding to the amino-acid se-
quence 3-213 of the protein, was fused at its N terminus to 
a 6His-tag, a spacer peptide (Ser-Ser-Gly-His-Ile) and the 
enterokinase recognition site (Asp-Asp-Asp-Asp-Lys). 
Overnight protein expression at room temperature in the 
BL21(DE3)pLysS E.coli strain (Invitrogen) afforded soluble 
protein in very high yield. Cells were lysed by sonication 
in TBS, pH 7.4 + 1 mM CaCl2. The cell lysate was first puri-
fied on a Ni-NTA column and then through a Sephacryl 
100 HR HiPrep 26/60 size exclusion column (GE 
Healthcare). Then, the protein was dialyzed in TBS buffer 
+ 20 mM CaCl2, digested with enterokinase (New England 
Biolabs) at 25° C, and passed over a Ni-NTA column to 
remove all traces of the cleaved 6His-tag, as well as any 
residual un-cleaved protein. The flow-through was then 
collected and further purified by size exclusion chroma-
tography with TBS + 1 mM CaCl2  and finally brought to a 
concentration of 12 mg/ml for crystallization experiments.  
 
Peptidomimetic design and synthesis 
The synthesis and characterization of FR159 has been 
described previously.36 Copies of the 1H and 13C NMR 
spectra and the HPLC-MS chromatogram are reported in 
the Supporting Information. HPLC-MS data were collect-
ed with an Agilent 1100 HPLC connected to a Bruker Es-
quire 3000+ ion trap mass spectrometer through an ES 
interface. FR159 was found to be ≥95% pure by LC-MS. 
 
Co-crystallization and data collection 
Crystals of the protein alone and the protein-ligand 
complex were obtained by the vapor diffusion method at 
room temperature from a 1.3 M ammonium sulfate, 80 
mMCaCl2, 0.1 M Tris pH 8.5 crystallization solution. Crys-
tals were then frozen in 25% (v/v) glycerol for X-ray dif-
fraction data collection. A 1.9 Å resolution data set and a 
2.13 Å data set were collected from a E-cadherin-(Val3)-
EC1EC2 crystal of 0.20 x 0.15 x 0.15 mm size and from a 
0.15 x 0.15 x 0.10 mm crystal of E-cadherin-(Val3)-EC1EC2 
in complex with FR159, respectively. In both cases, a λ = 
1.000 Å radiation in the X06DA-PXIII beamline at the 
Swiss Light Source (Paul Scherrer Institute, Villigen, Swit-
zerland) was used. Diffraction images were processed and 
scaled using XDS.39 Data collection and refinement statis-
tics are shown in Table 1. 
 
Structure determination 
The structure was determined by molecular replace-
ment using Molrep40 from the CCP4 package41 and the 
human E-cadherin-EC1EC2 crystal structure (PDB id: 
2O72) as the search probe. Model refinement was carried 
out using Refmac5 and Phenix.42,43 Water molecules were 
added both automatically using the program Phenix re-
fine43 and manually from visual inspection of the electron 
density map. Figures 3, 4 and 5 in the paper were generat-
ed using PyMOL (“www.pymol.org,”). The refinement 
converged to a final R/Rfree = 19.4/22.1 % for the un-ligated 
structure and R/Rfree = 18.5/23.0 % for the complex . 
 
CRYSTALLOGRAPHIC TABLE  
 E-cadherin-
EC1EC2 
E-cadherin-
EC1EC2 / FR159 
Space group 
Cell dimensions 
 a (Å) 
 b (Å) 
 c (Å) 
Wavelength (Å) 
Resolution (Å) 
Rsym or Rmerge (%) 
 I/σI 
Completeness (%) 
Multiplicity 
C 1 2 1 
 
120.45 
76.42 
73.02 
1.000 
42.66-1.92 
4.5 (17.6) 
8.4 (2.9) 
98.1 (96.2) 
2.0 
C 1 2 1 
 
120.58 
76.83 
72.77 
1.000 
42.26-2.13 
12.9 (12.3) 
7.3 (0.6) 
98.7 (93.5) 
6.0 
No. of reflections 
Rwork/Rfree (%) 
No. of atoms 
Protein 
Ligand (Ca2+/FR159)   
Water 
Average B-factors (Å2) 
Protein 
Ligand: Ca2+/FR159 
Water 
r.m.s.d. 
Bond lengths (Å) 
Bond angles (°) 
Ramachandran 
Most favored (%) 
Allowed (%) 
Disallowed (%) 
45679 
19.4 / 22.1 
 
3180 
6 
382 
 
46.20 
30.87 
47.68 
 
0.003 
0.513 
 
97 
3 
0 
33775 
18.5 / 23.0 
3196 
6 / 82 
229 
 
46.86 
32.18 / 73.68 
47.54 
 
0.003 
0.487 
 
97 
3 
0 
 
Table 1. Crystallographic data of the free and the ligand-
bound crystal structures of E-cadherin-EC1EC2 (PDB id: 
4ZT1 and 4ZTE, respectively). 
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